BioMarin Pharmaceutical Inc.
) ended the trading session on Apr 10, 2013 by reaching its
52-week high of $64.27. The company is expected to report its
first quarter 2013 results on Apr 25.
With more than 23% of year-to-date return and a long-term
expected earnings growth rate of 36.0%, this biopharmaceutical
company seems to be an attractive pick for long-term investors.
Average volume of shares traded over the last three months stands
at approximately 1,189K. The company had a market capitalization
of $8.1 billion on Apr 10.
On Feb 21, 2013, BioMarin reported higher-than-expected
revenues of $131.9 million on the back of higher product sales
for the final quarter of 2012. BioMarin expects to generate total
revenues in the range of $530-$555 million in 2013. The company
generated revenues of $500.7 million in 2012.
BioMarin's current approved products include Naglazyme
(MPS-VI), Aldurazyme (enzyme replacement therapy), Kuvan
(phenylketonuria) and Firdapse (LEMS). Naglazyme, the company's
highest contributor of revenues, is expected to generate around
$265-$285 million as product sales in 2013.
Multiple Pipeline-Related Events Lined Up
Moreover, BioMarin has a robust pipeline with several data
readouts expected this year. The company recently submitted a
submitted a Biologics License Application (BLA) to the US Food
and Drug Administration (FDA) for its lead candidate, Vimizim
(BMN-110, elosulfase alfa).
The candidate is developed for the treatment of patients
suffering from mucopolysaccharidosis Type IVA (MPS IVA) or
morquio A syndrome. The company expects the candidate to be
approved by the end of 2013. We believe investor focus to remain
on the regulatory status of Vimizim.
BioMarin's pipeline includes PEG-PAL (PEGylated recombinant
phenylalanine ammonia lyase) for the treatment of phenylketonuria
(PKU), BMN-673 - a poly polymerase inhibitor and BMN-701 for
Pompe's disease among others. On approval these candidates will
also drive growth at BioMarin.
Premium Valuation Justified
On a price-to-sales basis BioMarin is trading at 16.0x,
reflecting a huge premium of 363.8% compared with the peer group
average of 3.45x. On a price-to-book basis, the stock is also
trading at a premium to the peer group average. Given the
company's strong fundamentals, the premium valuation is
Other Stocks to Consider
BioMarin, a biopharma company, currently carries a Zacks Rank
#3 (Hold). However other biopharma stocks such as
) currently look more attractive and are worth considering. While
UCB and Athersys carry a Zacks Rank #1 (Strong Buy), Celgene
carries a Zacks Rank #2 (Buy).
ATHERSYS INC (ATHX): Free Stock Analysis
BIOMARIN PHARMA (BMRN): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.